Introduction {#sec1}
============

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, which accounts for 30% of all malignancy diagnosed in children and 80% of pediatric leukemia \[[@B1]\]. However, the etiology and biological mechanisms underlying ALL development have yet to be elucidated \[[@B2]\]. As for many cancers, the interactions between susceptibility genes and environmental factors are likely to implicate in the development of ALL. Epidemiological studies suggest that the imbalance of folate metabolism may be involved in predisposition to carcinogenesis, which is based on its involvement in both DNA biosynthesis and DNA methylation \[[@B5]\]. The low availability of folate causes uracil misincorporation into DNA replication, which leads to double-strand breakage and chromosomal deletion \[[@B6],[@B7]\]. Moreover, gene-specific hypermethylation and global DNA hypomethylation are two of the most frequently observed altered DNA methylation patterns in tumors \[[@B8],[@B9]\]. Accumulating studies have reported that polymorphisms in genes encoding folate-metabolizing enzymes disturb the balance of folate metabolism and have been associated with an altered predisposition to cancer \[[@B10]\].

The methionine synthase (MTR) plays a crucial role in the folate metabolic network. It is a vitamin B~12~-dependent enzyme, which remethylates homocysteine to methionine and simultaneously generates tetrahydrofolate by removing methyl group from 5-methyltetrahydrofolate. MTR helps to maintain the levels of adequate intracellular folate and normal homocysteine and methionine concentrations, which are used for proper DNA methylation or other methylation processes \[[@B13]\]. The *MTR* gene is mapped on 1q43, and the extensively investigated A2756G polymorphism (rs1805087) leads to a change from aspartate to glycine at codon 919 (D919G), resulting in reduced enzyme activity \[[@B14]\]. It has been reported that this polymorphism can increase homocysteine levels through suppressing methionine metabolism and consequentially can lead to DNA hypomethylation and promote tumorigenesis \[[@B15],[@B16]\]. Plenty of studies have found that *MTR* A2756G polymorphism has been linked to various cancer, such as prostate cancer, retinoblastoma and lymphoma \[[@B17]\]. A number of studies have attempted to explore the effect of *MTR* A2756G polymorphism on pediatric ALL risk, yet the reported results are inconsistent. The inconsistencies of results might be attributed to some variables in study of population like genetic backgrounds difference and relatively small size of sampling in single study. Therefore, a meta-analysis was conducted to derive a more precise estimation of the association between *MTR* A2756G polymorphism and genetic susceptibility to pediatric ALL.

Methods {#sec2}
=======

Identification and eligibility of relevant studies {#sec2-1}
--------------------------------------------------

The present study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The PubMed, Embase, Google Scholar, Web of Science, ScienceDirect, Wanfang Databases and China National Knowledge Infrastructure were systematically searched to identify the published case--control studies on the relationship between *MTR* A2756G polymorphism and pediatric ALL risk with the following subject terms or keywords: 'methionine synthase' or 'MTR' or 'MS' or '5-methyltetrahydrofolate-homocysteine methyltransferase', 'polymorphism' or 'variation' or 'variant' or 'mutation', 'acute lymphoblastic leukemia' or 'leukemia' or 'ALL', and 'pediatric' or 'children' or 'childhood'. The latest web-based literature search was conducted on May 20, 2018 and no language restriction was applied. In addition, the reference lists in the primary studies and review articles were also examined manually to identify additional potentially relevant studies.

Inclusion criteria {#sec2-2}
------------------

The following inclusion criteria were applied for selecting literature: (1) confirmed diagnosis for the pediatric ALL cases; (2) case--control study; (3) available genotypes distribution data for both patients and control populations; (4) genotypes distribution of the control group must be in consistent with Hardy--Weinberg equilibrium (HWE). The case reports, letters, commentary and review articles were excluded. If the same or overlapping patient population was reported by several articles, only the most recent or largest sample size was chose in this meta-analysis.

Quality assessment {#sec2-3}
------------------

The quality assessment of included studies was preformed independently by two authors according to the Newcastle-Ottawa Scale (NOS). Discrepancies were adjudicated by the third investigator until consensus was achieved. The NOS is a tool used for assessing the quality of non-randomized studies included in a systematic review and meta-analysis \[[@B20]\]. Using the tool, each study is judged on eight items, categorized into three groups: the study group selection, the comparability of the groups, and the ascertainment of exposure. Stars are awarded such that the highest quality studies are awarded up to nine stars. In this meta-analysis, studies with more than six stars were identified as high quality.

Data collection {#sec2-4}
---------------

From each of the included articles, the following data were collected independently by two authors: the name of first author, year of publication, country and ethnicity of participants, source of controls, total number of cases and controls, genotyping methods, genotyping data of the *MTR* A2756G polymorphism in cases and controls. Any disagreement was resolved by re-evaluation of the originally included studies.

Statistical analysis {#sec2-5}
--------------------

For the controls of each study, the *χ^2^*-test was adopted to check HWE of genotypes distribution frequencies, with *P*\<0.05 indicating deviation from HWE. The strength of association between *MTR* A2756G polymorphism and pediatric ALL risk was assessed by calculating pooled ORs and corresponding 95% CIs under the allele model (G allele vs. A allele), heterozygote model (AG vs. AA), homozygote model (GG vs. AA), recessive model (GG vs. AA+AG) and dominant model (AG+GG vs. AA), respectively. The significance of the overall ORs was determined by the *Z*-test. The *χ^2^*-test based *Q*-test was performed to estimate the heterogeneity across the eligible studies, and the heterogeneity was further quantified with *I*^2^-test. When *P*\>0.05, showing that the effects were assumed to be homogeneous, the fixed-effects model (Mantel--Haenszel method) was selected to calculate the ORs, alternatively, the random-effects model (DerSimonian--Laird method) was used \[[@B21]\]. Stratification analyses were performed by ethnicity (Asian and Caucasian), control source (hospital-based and population-based) and NOS score (low quality and high quality). Sensitivity analysis was conducted by excluding one study each time and recalculating the ORs with corresponding 95%CIs to assess the stability of combined results. The qualitative funnel plot was employed to assess publication bias by calculating the standard error of log(OR) of each study plotted against its log(OR), and the funnel plot asymmetry was further assessed using quantitative Egger's test \[[@B22]\]. All the statistical tests were done with RevMan v5.3 (The Cochrane Collaboration, Oxford, U.K.) and STATA v12.0 (Stata Corporation, College Station, TX). All *P* values were two-sided, and *P*\<0.05 was considered statistically significant.

Results {#sec3}
=======

Characteristics of included studies {#sec3-1}
-----------------------------------

The flow diagram of literature selection was presented in [Figure 1](#F1){ref-type="fig"}. After duplicates removed, 49 relevant articles were identified based on an extensive search. After glancing the titles and abstracts, 36 irrelevant studies and reviews were excluded and three full-text articles were excluded during the further assessment. Finally, a total of ten case--control studies met our inclusion criteria, including 3224 ALL cases and 4077 matched controls \[[@B23]\]. [Table 1](#T1){ref-type="table"} presented the main characteristics of eligible studies. Of these included studies, there were nine studies carried out among Caucasians \[[@B23]\], and one study among Asian descents \[[@B32]\]. When classified by the source of controls, one study was hospital-based \[[@B26]\] and nine were population-based designed \[[@B23],[@B27]\]. Three studies were divided into low quality and seven were assigned as high quality. The genotypes distribution frequencies among the controls were in agreement with HWE for all included studies. The genotyping data of *MTR* A2756G polymorphism in cases and controls from the individual studies were shown in [Table 2](#T2){ref-type="table"}.

![Flow diagram of study selection process](bsr-39-bsr20181770-g1){#F1}

###### Main characteristics of studies included in the meta-analysis

  Reference                          Year   Country       Ethnicity   Control source   Genotyping methods       Quality score
  ---------------------------------- ------ ------------- ----------- ---------------- ------------------------ ---------------
  de Jonge et al. \[[@B23]\]         2009   Netherlands   Caucasian   PB               PCR-RFLP                 5
  Gast et al. \[[@B24]\]             2007   Germany       Caucasian   PB               Allelic discrimination   8
  Kamel et al. \[[@B25]\]            2007   Egypt         Caucasian   PB               PCR-RFLP                 6
  Lautner-Csorba et al. \[[@B26]\]   2013   Hungary       Caucasian   HB               MassARRAY                7
  Lightfoot et al. \[[@B27]\]        2010   U.K.          Caucasian   PB               TaqMan Assay             9
  Metayer et al. \[[@B28]\]          2011   U.S.A.        Caucasian   PB               GoldenGate Assay         8
  Milne et al. \[[@B29]\]            2015   Australia     Caucasian   PB               PCR-RFLP                 9
  Petra et al. \[[@B30]\]            2007   Slovenia      Caucasian   PB               PCR-RFLP                 5
  Rahimi et al. \[[@B31]\]           2012   Iran          Caucasian   PB               PCR-RFLP                 7
  Nikbakht et al. \[[@B32]\]         2012   India         Asian       PB               PCR-RFLP                 9

Abbreviations: HB, hospital-based; PB, population-based; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism.

###### Genotypes distribution of *MTR* A2756G polymorphism in cases and controls

  Reference                          Sample size   Case group   Control group                                                         
  ---------------------------------- ------------- ------------ --------------- ----- ---- ------ ----- ----- ----- ---- ------ ----- ------
  de Jonge et al. \[[@B23]\]         245           489          162             74    9    398    92    340   137   12   817    161   0.68
  Gast et al. \[[@B24]\]             446           547          280             153   13   713    179   375   151   21   901    193   0.24
  Kamel et al. \[[@B25]\]            87            306          55              29    3    139    35    194   97    15   485    127   0.53
  Lautner-Csorba et al. \[[@B26]\]   543           529          344             175   24   863    223   341   163   25   845    213   0.34
  Lightfoot et al. \[[@B27]\]        870           759          531             288   51   1350   390   510   223   26   1243   275   0.79
  Metayer et al. \[[@B28]\]          376           447          237             123   16   597    155   292   137   18   721    173   0.70
  Milne et al. \[[@B29]\]            391           514          251             130   10   632    150   337   158   19   832    196   0.93
  Petra et al. \[[@B30]\]            68            258          51              16    1    118    18    161   82    15   404    112   0.30
  Rahimi et al. \[[@B31]\]           73            128          42              26    5    110    36    75    47    6    197    59    0.69
  Nikbakht et al. \[[@B32]\]         125           100          74              44    7    192    58    58    35    7    151    49    0.59

Abbreviations: HWE, Hardy--Weinberg equilibrium; *MTR*, methionine synthase.

Quantitative data synthesis {#sec3-2}
---------------------------

[Table 3](#T3){ref-type="table"} listed the main results of quantitative synthesis. When all eligible studies were pooled together, the results found that there was statistically significant association between *MTR* A2756G polymorphism and risk of pediatric ALL under three genetic models (AG vs. AA: OR = 1.13, 95%CI = 1.02--1.26, *P* = 0.02; AG+GG vs. AA: OR = 1.13, 95%CI = 1.02--1.25, *P* = 0.01; G allele vs. A allele: OR = 1.10, 95%CI = 1.01--1.20, *P* = 0.03) ([Figure 2](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). In the stratification analyses according to ethnicity, control source and quality score, significant association was also found in Caucasians, population-based designed studies, and studies assigned as high quality ([Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}, [Table 3](#T3){ref-type="table"}).

![Forest plot describing the association of *MTR* A2756G polymorphism and pediatric ALL risk (AG+GG vs. AA)](bsr-39-bsr20181770-g2){#F2}

![Forest plot describing the association of *MTR* A2756G polymorphism and pediatric ALL risk (G allele vs. A allele; stratified by ethnicity)](bsr-39-bsr20181770-g3){#F3}

![Forest plot describing the association of *MTR* A2756G polymorphism and pediatric ALL risk (AG vs. AA; stratified by quality score)](bsr-39-bsr20181770-g4){#F4}

###### Results of meta-analysis for *MTR* A2756G polymorphism with pediatric ALL risk

  Variables        No.   Sample size   AG vs. AA   GG vs. AA           GG vs. AA+AG   AG+GG vs. AA   G Allele vs. A Allele                                                                                                                 
  ---------------- ----- ------------- ----------- ------------------- -------------- -------------- ----------------------- ------ ------ ------------------- ------ ------ ------------------- ------- ------ ------------------- ------ ------
  Overall          10    3224          4077        1.13 (1.02--1.26)   0.02           0.65           1.10 (0.86--1.39)       0.45   0.28   1.05 (0.83--1.34)   0.66   0.33   1.13 (1.02--1.25)   0.01    0.38   1.10 (1.01--1.20)   0.03   0.18
  Ethnicity                                                                                                                                                                                                                                
  Caucasian        9     3099          3977        1.14 (1.03--1.27)   0.01           0.58           1.11 (0.87--1.42)       0.39   0.23   1.07 (0.84--1.37)   0.58   0.27   1.14 (1.03--1.26)   0.01    0.33   1.11 (1.02--1.21)   0.02   0.15
  Asian            1     125           100         0.99 (0.56--1.73)   0.96                          0.78 (0.26--2.36)       0.66          0.79 (0.27--2.33)   0.67          0.95 (0.56--1.62)   0.86           0.93 (0.60--1.44)   0.75   
  Control source                                                                                                                                                                                                                           
  PB               9     2681          3548        1.15 (1.03--1.28)   0.02           0.58           1.13 (0.87--1.47)       0.37   0.23   1.08 (0.83--1.41)   0.55   0.27   1.15 (1.03--1.28)   0.01    0.33   1.11 (1.02--1.22)   0.02   0.15
  HB               1     543           529         1.06 (0.82--1.38)   0.64                          0.95 (0.53--1.70)       0.87          0.93 (0.53--1.65)   0.81          1.05 (0.82--1.35)   0.71           1.03 (0.83--1.27)   0.82   
  Quality                                                                                                                                                                                                                                  
  High             7     2824          3024        1.16 (1.04--1.30)   0.008          0.83           1.14 (0.88--1.48)       0.32   0.29   1.09 (0.84--1.41)   0.52   0.31   1.16 (1.04--1.29)   0.006   0.71   1.12 (1.03--1.23)   0.01   0.49
  Low              3     400           1053        1.00 (0.77--1.29)   0.97           0.23           0.86 (0.45--1.64)       0.65   0.16   0.87 (0.45--1.66)   0.67   0.20   0.98 (0.77--1.26)   0.89    0.10   0.90 (0.60--1.35)   0.60   0.05

*P*~h~ value used to evaluate the heterogeneity between included studies. ALL, acute lymphoblastic leukemia; CI, confidence interval; HB, hospital-based; *MTR*, methionine synthase; OR, odds ratio; PB, population-based.

Heterogeneity and sensitivity analysis {#sec3-3}
--------------------------------------

No significant heterogeneity was detected across the eligible studies under all five genetic models for *MTR* A2756G polymorphism, so the fixed-effects model based Mantel--Haenszel method was selected for the combined analysis ([Table 3](#T3){ref-type="table"}). Sensitivity analysis, in which the pooled ORs were recalculated after sequential omission of individual studies, revealed that the combined results remained virtually unchanged, suggesting the robustness of quantitative synthesis results.

Publication bias {#sec3-4}
----------------

The shapes of funnel plots appeared symmetrical, suggesting that there was no obvious publication bias ([Figures 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). In addition, the results of Egger's test also indicated a lack of publication bias of the current meta-analysis.

![Funnel plot assessing publication bias in heterozygote model (AG vs. AA)](bsr-39-bsr20181770-g5){#F5}

![Funnel plot assessing publication bias in dominant model (AG+GG vs. AA)](bsr-39-bsr20181770-g6){#F6}

Discussion {#sec4}
==========

*MTR* gene encodes a vitamin B~12~-dependent enzyme, which catalyzes the remethylation of homocysteine to methionine, the precursor to S-adenosylmethionine, which acts as the universal methyl group donor \[[@B33]\]. The MTR reaction also releases tetrahydrofolate, which is remethylated to 5,10-methylene tetrahydrofolate for further participating in nucleotide synthesis. It is reported that *MTR* A2756G polymorphism can convert the codon for aspartate to glycine, resulting in a lower enzyme activity followed by homocysteine elevation and DNA hypomethylation \[[@B14],[@B15]\]. In addition, the G-variant could enhance the flux of one-carbon moieties available for DNA methylation \[[@B13]\]. Therefore, *MTR* A2756G polymorphism might lead to alterations in DNA biosynthesis and methylation pattern, and contribute to the genetic susceptibility to cancer including leukemia, as hypermethylation is important in acute leukemia \[[@B34],[@B35]\].

Numerous investigations have examined the association of *MTR* A2756G polymorphism with pediatric ALL susceptibility, yet have generated conflicting results. Petra et al. \[[@B30]\] found that the presence of at least one polymorphic *MTR* 2756 G allele showed some, but insignificant, tendency to reduce the risk for pediatric ALL. However, a dose--response relationship between the number of copies of the *MTR* 2756 G allele and increased risk of pediatric ALL was observed in the study by Lightfoot et al. \[[@B27]\]. Specifically, heterozygosity for the variant allele (AG) was associated with a 1.24-fold increased risk of ALL (95%CI = 1.00--1.53, *P* = 0.05), and homozygosity (GG) with a 1.88-fold increased risk of ALL (95%CI = 1.16--3.07, *P* = 0.01). de Jonge et al. \[[@B23]\] found no statistical differences in genotype distribution for *MTR* A2756G polymorphism between children ALL and the controls. To elucidate this inconsistency, a meta-analysis was conducted to derive a more precise estimation of the association.

In the present study, the combined results found that there was significant association between *MTR* A2756G polymorphism and risk of pediatric ALL in overall comparison. Individuals with the *MTR* 2756 G allele had increased risk of developing pediatric ALL compared to those with the A allele. Moreover, individuals with the AG genotype or the AG+GG genotype had raised risk of pediatric ALL compared to those with the AA genotype. Significant association was also found in Caucasians, population-based designed studies, and studies assigned as high quality. Our results were in accordance with the conclusion reported by Xia et al. \[[@B36]\], which showed *MTR* 2756 A allele was associated with a decreased risk of pediatric ALL compared with the G allele. In present meta-analysis, more web-based databases including English and non-English databases were systematically searched to minimize the selection bias and the potential risk of missing eligible literature \[[@B37]\]. Since our analysis included several new studies and included 3224 cases and 4077 controls, allowing for sufficient statistical power and more precise estimation, our conclusion is more credible.

When interpreting the results, some limitations of our meta-analysis should be considered. First, our results were based on unadjusted estimates, which may cause confounding bias. A more precise analysis could be performed if all raw data were available, which would allow for the adjustment by other confounders including sex, age, lifestyles and other potential factors. Second, the quantitative synthesis of some subgroups may have no sufficient testing power to accurately assess the real association, for instance, only one study was conducted among Asians. In addition, the gene--environment interactions which may modify genetic susceptibility to cancer were not taken into account in the present study due to the limited data. Last but not least, we also did not consider other genes in folate metabolic network that might be associated with the risk of pediatric ALL. The etiological mechanism of ALL is very complicated, in which gene--gene, and gene--environment interactions are involved \[[@B4],[@B38]\]. Several case--control studies have reported that *MTR* 2756AG individuals who were *SHMT1* 1420CT/TT had a 5.6-fold reduction in ALL risk \[[@B39]\]. In contrast, *MTR* 2756 G was a risk allele for ALL on itself but also in combination with the *MTHFR* 677 T allele in adults \[[@B38]\]. The possibility cannot be ruled out that the role of *MTR* A2756G polymorphism is somewhat diluted or concealed by other gene--gene interactions. Future studies combining other genes in folate metabolism with *MTR* are encouraged.

Conclusion {#sec5}
==========

In conclusion, this meta-analysis suggests that *MTR* A2756G polymorphism influences the genetic susceptibility to pediatric ALL, especially in Caucasians. However, large scale and well-designed studies are required to validate our findings, and the biochemical mechanism and function of *MTR* A2756G polymorphism should also be investigated in the future.
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